date,title,source
Oct-22-18,"Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist",PR Newswire
Nov-13-18,Kleo Pharmaceuticals Secures $21 Million to Advance Novel Small Molecule Cancer Immunotherapies,PR Newswire
Nov-14-18,Migraine-Focused Biotech Has A Headache On Quarterly Losses,Investor's Business Daily
Nov-14-18,Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results,PR Newswire
